Insights

More Articles Back to Article

EU OKs Merck, MSD's Keytruda combo as first-line kidney cancer therapy

The European Commission has approved Merck and MSD's Keytruda, in combination with Pfizer's Inlyta, or axitinib, as a first-line treatment for patients with renal cell carcinoma. In a late-stage trial, the combination drug reduced death risk in patients with RCC by 47% versus Pfizer's Sutent, or sunitinib. PharmaPhorum (UK) (9/5)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!